Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Atai Beckley Inc.NASDAQ: ATAI

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation growth accelerates

Q2 FY2026 stock-based compensation of $7.44M rose 177.0% year over year, ahead of the -17.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 36.5% from the prior quarter.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, down 8276.0 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +177.0% holds above the trailing-twelve-month pace of -17.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$7.44M+36.5% QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMJun 2026
$16.18M-17.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+177.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How ATAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -17.0% is the 6th highest of 11, against a peer median of -10.7%.
  • Stock-based compensation amounts to 361.7% of revenue for ATAI, versus a peer median of 244.7%.
ATAI Competitors
Stock-Based Compensation for ATAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$49.18M USD+10.5%+43.7%22.6%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$48.31M USD-34.7%+3.6%466.8%
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$41.68M USD+54.1%+120.1%—
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$34.27M USD+82.5%+146.7%1800.0%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$31.2M USD+11.4%+8.4%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$25.38M USD+66.4%——
SANASana Biotechnology, Inc.LTM Mar 2026$24.1M USD-32.3%-12.7%—
ATAIAtai Beckley Inc.LTM Jun 2026$16.18M USD-17.0%—361.7%
NKTRNektar TherapeuticsLTM Jun 2026$11.99M USD-31.8%-39.6%22.0%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$11.34M USD-79.7%-18.3%872.4%
IMTXImmatics N.V.LTM Mar 2026€7.38M EUR-44.8%—19.8%
Peer median (excluding ATAI) —-10.7%+6.0%244.7%

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(174.24M)(157.42M)(43.9M)(150.05M)(660.05M)
Depreciation & Amortization47K168K319K473K1.01M
Deferred Income Tax39.14M5.07M000
Stock-Based Compensation63.36M42.38M32.98M25.49M0
Change in Working Capital(7.6M)(3.34M)7.47M(9.2M)(6.48M)
Accounts Receivables00000
Inventory00000
Accounts Payables2.3M(3.03M)2.14M(1.87M)(1.7M)
Other Working Capital(9.9M)(301K)5.33M(7.33M)(4.78M)
Other Non-Cash Items16.06M8.67M(80.99M)50.85M562.84M
Operating Cash Flow(63.25M)(104.47M)(84.12M)(82.44M)(102.68M)
Capital Expenditures(1.13M)(1.02M)(590K)(95K)(901K)
Acquisitions (Net)(52.94M)0(443K)359K4.64M
Purchases of Investments(23.66M)(309.66M)(186.22M)(15M)(98.95M)
Sales of Investments(955K)226.83M139.47M82.01M9.05M
Other Investing Activities(2.6M)(3.25M)(5.84M)(8.1M)(13M)
Investing Cash Flow(81.28M)(86.85M)(53.3M)59.17M(109.13M)
Debt Repayment1.59M15M05M7.71M
Common Stock Issued409.88M00535K283.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.42M5.19M(8.36M)(161K)(21.66M)
Financing Cash Flow409.86M20.79M(8.36M)5.37M269.48M
Effect of Forex Changes(320K)(1.12M)189K362K116K
Net Change in Cash265.02M(171.65M)(145.58M)(17.53M)57.8M
Free Cash Flow(64.37M)(105.49M)(84.71M)(82.53M)(103.58M)

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.